NEW YORK (GenomeWeb News) – Bruker today reported that its third-quarter revenues increased 7 percent year over year, easily beating consensus Wall Street estimates on the top and bottom line.

The Billerica, Mass.-based scientific instruments maker reported total revenues of $447.8 million for the three months ended Sept. 30, compared to $418.4 million. Analysts, on average, had forecasted $421.4 million in sales.

Excluding the effects of acquisitions and foreign currency translation, Bruker's Q3 revenues were up 14 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.